Exploration of potential active ingredients and mechanism of action of Xihuang pill-medicated serum against glioma based on HPLC-Q-TOF-MS/MS,network pharmacology and experimental verification
Qualitative analysis of the ingredients absorbed into blood and their metabolites of Xihuang pill(XHP)were conducted using high-performance liquid chromatography quadrupole time-of-flight mass spectrometry(HPLC-Q-TOF-MS/MS)technology.Network pharmacology was used to explore the potential anticancer mecha-nisms of the ingredients against glioma,and their specific mechanisms were validated through molecular docking and experimental verification.SD rats were intragastrically administered with XHP,and rat serum samples were collected.Ingredients absorbed into blood and their metabolites were identified based on the retention time of chromatographic peaks,accurate molecular mass,characteristic fragment ions,and comparisons with reference substances and literature data.PharmMapper and SwissTarget Prediction databases were used to obtain the targets of the XHP-medicated serum,while GeneCards,OMIM,PharmGKB,TTD,and DrugBank databases were used to obtain glioma disease targets.The"component-target"network relationship diagram was constructed using Cytoscape 3.9.1 software.The protein-protein interaction(PPI)network diagram was constructed using the STRING database,and the targets were analyzed using GO and KEGG analyses.Molecular docking was used to verify the binding ability of core targets with their corresponding compounds in XHP-medicated serum.The potential mecha-nism of the anti-glioma effect of 11-keto-β-boswellic acid(KBA),a representative component of XHP-medicated serum,was verified using CCK-8 and Western blot assays.A total of 40 compounds were identified in the XHP-medicated serum,including 28 prototype components and 12 metabolites.The network pharmacology results showed that elemonic acid,3-acetyl-β-boswellic acid,KBA,α-boswellic acid,and other 5 compounds might be the active ingredients of XHP-medicated serum in the treatment of glioma.Glutathione reductase(GSR),glucose-6-phosphate dehydrogenase(G6PD),ATP-citrate lyase(ACLY),aldo-keto reductase family 1 member B1(AKR1B1)and glutaredoxin(GLRX)were identified as key targets,involving pathways such as glutathione metabolism and the pentose phosphate pathway.Further cell experiments showed that KBA significantly inhibited the proliferation of T98G cells with an IC50 of 30.96 µmol·L-1,and KBA(30 μmol·L-1)significantly downregulated the protein expression levels of GSR in T98G cells.In summary,XHP-medicated serum may exert its anti-glioma effect by regulating GSR and G6PD-targeted pathways involved in glutathione metabolism.These results provide valuable evidence for further investigating the mechanism of XHP in treating glioma.The animal welfare and experimental procedures were approved by the Ethical Committee of Laboratory Animals at Nanjing University of Chinese Medicine(approval No.ACU221001).
Xihuang pillmedicated serumHPLC-Q-TOF-MS/MSingredient absorbed into bloodglioma
万方数据
维普
